These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11435535)

  • 1. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.
    Benenati J; Shlansky-Goldberg R; Meglin A; Seidl E;
    J Vasc Interv Radiol; 2001 Jul; 12(7):795-805. PubMed ID: 11435535
    [No Abstract]   [Full Text] [Related]  

  • 2. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
    Rocha-Singh KJ; Trokey J
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):457-60. PubMed ID: 11948891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The FINESSE trial].
    Petronio AS; Piscione F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):1-5. PubMed ID: 19292014
    [No Abstract]   [Full Text] [Related]  

  • 6. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
    Tepe G; Hopfenzitz C; Dietz K; Wiskirchen J; Heller S; Ouriel K; Ziemer G; Claussen CD; Duda SH
    Radiology; 2006 Jun; 239(3):892-900. PubMed ID: 16641342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
    Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
    J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
    Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ
    Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
    Nordt TK; Peter K; Bode C
    Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab.
    Drescher P; McGuckin J; Rilling WS; Crain MR
    AJR Am J Roentgenol; 2003 May; 180(5):1385-91. PubMed ID: 12704056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.
    Drescher P; Crain MR; Rilling WS
    J Vasc Interv Radiol; 2002 Jan; 13(1):37-43. PubMed ID: 11788692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
    Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
    Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
    Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Beyer ME; Hoffmeister HM
    Drugs Exp Clin Res; 2004; 30(2):47-54. PubMed ID: 15272642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful revascularization of acute carotid stent thrombosis by facilitated thrombolysis.
    Steiner-Böker S; Cejna M; Nasel C; Minar E; Kopp CW
    AJNR Am J Neuroradiol; 2004 Sep; 25(8):1411-3. PubMed ID: 15466343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
    Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitated percutaneous intervention following combination therapy with reteplase and abciximab for acute myocardial infarction.
    Weinstock BS
    J Invasive Cardiol; 2002 Feb; 14(2):100-4; quiz 104-5. PubMed ID: 11818648
    [No Abstract]   [Full Text] [Related]  

  • 20. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.